Medicus Pharma (MDCX) announced that its Phase 2 clinical study evaluating safety and efficacy of Doxorubicin Microneedle Array to non-invasively treat nodular basal cell carcinoma of the skin, has successfully completed enrolment of ninety patients in the United States. The phase 2 clinical study is currently underway in nine (9) clinical sites in United States. The company expects to release topline results for SKNJCT-003 in the first quarter of 2026 and secure an end of phase 2 meeting with the FDA in the first half of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma’s Warrant Inducement Agreement Announced
- Medicus Pharma Ltd. Strengthens Leadership and Expands Clinical Trials
- Medicus Pharma appoints Carolyn Bonner as CFO
- Medicus Pharma explores novel treatment innovations for prostate, skin cancers
- Medicus Pharma files to sell 2.68M common shares for holders